AbstractPhase I/II studies of gemtuzumab ozogamicin (GO) in pediatric refractory/relapsed acute myeloid leukemia (AML) have been reported. We present the cases of two children with relapsed AML who were treated with GO plus cytarabine, leading to a decrease of minimal residual disease down to levels not previously obtained. The toxicity profile of this treatment was relatively mild, except for severe but manageable myelosuppression.
Figures & Tables
Vol. 91 No. 3 (2006): March, 2006 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com